Phase I dose-escalation study of CYT997 given as a 24-hour intravenous infusion every three weeks in patients with advanced solid tumours

Trial Profile

Phase I dose-escalation study of CYT997 given as a 24-hour intravenous infusion every three weeks in patients with advanced solid tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Lexibulin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors YM BioSciences Australia
  • Most Recent Events

    • 08 Sep 2010 Results from this trial have been published in the British Journal of Cancer according to a YM Biosciences media release. The results are discussed further within the media release.
    • 24 Aug 2010 Results from this trial were published in the British Journal of Cancer.
    • 26 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top